The goal of this study is to craft empirically grounded, practical policy proposals that address tensions between ethical needs for explainability and legitimate commercial needs for trade secrecy raised by AI-based clinical decision software, including diagnostic, treatment, and predictive software. The study will examine both AI-enabled software that is regulated as a medical device by the FDA as well as unregulated software.